Vanguard Group Inc. Decreases Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Vanguard Group Inc. reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,207,497 shares of the company's stock after selling 90,759 shares during the quarter. Vanguard Group Inc. owned about 4.44% of Kiniksa Pharmaceuticals worth $63,444,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $354,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth approximately $1,105,000. Wellington Management Group LLP purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $1,192,000. Jane Street Group LLC lifted its position in Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company's stock valued at $8,624,000 after purchasing an additional 315,456 shares during the period. Finally, Franklin Resources Inc. grew its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after purchasing an additional 1,100 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock traded down $0.15 during trading on Thursday, reaching $20.39. 56,040 shares of the stock traded hands, compared to its average volume of 612,135. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -145.63 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The business has a fifty day simple moving average of $21.03 and a two-hundred day simple moving average of $21.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. During the same period last year, the business posted $0.35 earnings per share. The company's revenue for the quarter was up 46.9% compared to the same quarter last year. On average, research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on KNSA shares. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $37.17.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 12,000 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00. Following the completion of the sale, the chief operating officer now directly owns 77,363 shares in the company, valued at approximately $1,584,394.24. The trade was a 13.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,766 shares of company stock valued at $2,002,135. 54.57% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.